Skip to main content


Meet with our product experts in one-on-one virtual sessions

Set Up a Meeting
Quick Connect

White Paper

Rivaroxaban from Dr.Reddy’s: Full basket offerings of API and Finished formulations

Dr. Reddy’s is among the earliest generic API manufacturers globally for Rivaroxaban API and filed the USDMF in March 2014. 

Dr. Reddy’s process involves a selective and efficient chemical transformations that offer distinctive advantage for quality and manufacturability. The process eliminates the potential impurities formed in the process, and can be robust and safely operated at a commercial scale.

In selected markets, we can also provide the formulated drug product of Rivaroxaban and will support you in all regulatory aspects from filing to registration.

To know more about our Rivaroxaban offerings, read the tech sheet by filling the contact form below. 

Explore other Whitepapers:

Know More

Download Now

Please fill the Contact form below in order to view the white paper

Disclaimer

No information in this catalog - including any reference to any product or service - constitutes an offer for sale, or be construed as representing an offer for sale. Products protected under valid patents are not offered or supplied for commercial use. However, the research quantities of such products may be offered for the purpose of regulatory submissions, wherever such regulatory exemptions exist. The buyers should make their independent evaluation of the patent scenario for their respective markets and will be responsible for all patent related liabilities. Products protected under valid patents in India are not available for commercial use but would be available for Section 107A purposes.